Background and objective:Botulinum toxin type A(BoNT/A)is a metalloprotease that blocks synaptic transmission via the cleavage of a synaptosomal-associated protein of 25 kDa(SNAP-25).It has gained widespread use as a ...Background and objective:Botulinum toxin type A(BoNT/A)is a metalloprotease that blocks synaptic transmission via the cleavage of a synaptosomal-associated protein of 25 kDa(SNAP-25).It has gained widespread use as a treatment for cerebral palsy and skeletal muscle hypertrophy.In China,Chinese botulinum toxin type A(CBTX-A),a type of BoNT/A,is in widespread clinical use.However,the changes in the morphological and biochemical properties of treated muscles and in remote muscles from the CBTX-A injection site are relatively unknown.Therefore,we investigated the changes in histomorphology and myosin heavy chain(MyHC)isoform composition and distribution in rat gastrocnemius muscles after intramuscular injection of CBTX-A.Methods:The weakness of the injected muscles was assessed periodically to identify their functional deficiency.Muscle slices were stained with hematoxylin-eosin(HE)and adenosine triphosphatase(ATPase).MyHC isoform composition was analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis(SDS-PAGE)to uncover changes in morphological and biochemical properties.Results:Our findings demonstrate that following injection of CBTX-A 5 U into rat gastrocnemius muscles,shifts in MyHC isoform composition emerged on the third day after injection and peaked in the fourth week.The composition remained distinctly different from that of the control group after the twelfth week.More specifically,there was a decrease in the proportion of the type IIb isoform and an increase in the proportions of type IIx,type IIa,and type I isoforms.Conclusions:Data revealed that CBTX-A led to a shift in MyHC composition towards slower isoforms and that the MyHC composition remained far from normal six months after a single injection.However,no noticeable remote muscle weakness was induced.展开更多
Background:Benign essential blepharospasm(BEB),aberrant facial nerve degeneration and hemifacial spasm(HFS)are all examples dystonia which,though not life-threatening,can have a significant impact on patient quality o...Background:Benign essential blepharospasm(BEB),aberrant facial nerve degeneration and hemifacial spasm(HFS)are all examples dystonia which,though not life-threatening,can have a significant impact on patient quality of life.The need for reliable self-rating surveys to monitor functional disability is fundamental.The Blepharospasm Disability Index(BSDI)is already a widely utilised and validated selfrating score for blepharospasm whilst the functional disability score(FDS)requires further validation.The principle aim of this study is to repeat validation of the FDS against the BSDI,which has been validated by several groups since its original description but only in patients with BEB.Methods:A randomised blinded prospective cohort study was conducted at a single unit on 38 patients with BEB,aberrant facial nerve degeneration and HFS.Patients were blinded to complete the FDS followed by the BSDI or the BSDI followed by the FDS with a 30-minute interval.Results:Both the FDS and BSDI were found to be reliable with high internal consistency and test-retest reliability.Both scales were also found to be moderately correlated with the Jankovic disease severity score.Conclusions:This study is the first to use the FDS as a rating scale in patients with HFS and aberrant facial nerve degeneration.It is also the first study to formally validate the FDS as an acceptable rating scale for patients with dystonia and in particular it provides validation for its use in patients with HFS and aberrant facial nerve degeneration.展开更多
目的建立间接ELISA,检测血清中抗A型肉毒神经毒素(botulinum neurotoxin type A, BoNT-A)中和抗体。方法以纯化的BoNT-A作为包被抗原,抗BoNT-A兔血清作为一抗,辣根过氧化物酶(horseradish peroxidase, HRP)标记的金黄色葡萄球菌蛋白A(St...目的建立间接ELISA,检测血清中抗A型肉毒神经毒素(botulinum neurotoxin type A, BoNT-A)中和抗体。方法以纯化的BoNT-A作为包被抗原,抗BoNT-A兔血清作为一抗,辣根过氧化物酶(horseradish peroxidase, HRP)标记的金黄色葡萄球菌蛋白A(Staphylococal Protein A, SPA)作为二抗,结合实验设计,建立检测血清中抗BoNT-A中和抗体的间接ELISA,验证该方法的特异性、灵敏度和重复性,并与经典动物中和试验法检测抗BoNT-A中和抗体的结果进行比较。结果①间接ELISA条件的建立与优化,使用2.50μg/mL纯化的BoNT-A抗原包被,4℃过夜;1%明胶作为封闭剂,37℃封闭2 h;确定一抗优化条件:反应条件为1∶5 000稀释,37℃孵育90 min;二抗优化条件:反应条件为1∶10 000稀释,37℃孵育90 min;加入底物37℃显色10 min,加终止液终止后,用酶标仪测定A450 nm值;②经过验证该方法特异性好,所包被抗原与抗伤寒杆菌兔血清、抗破伤风毒素兔血清、抗B型肉毒毒素兔血清、抗E型肉毒毒素兔血清、抗F型肉毒毒素兔血清均无交叉反应;灵敏度高,当抗BoNT-A兔血清按照1∶320 000稀释时,检测结果依然呈阳性;重复性良好,批内重复性验证CV分别为2.62%、1.40%、2.14%,变异系数均小于3%,批间差异无统计学意义(P=0.103,P>0.05);该方法检测抗BoNT-A中和抗体检出限为抗-0.03 LD50/mL,大约是经典动物中和试验法的1/30,显著地提高了检测灵敏度。结论建立了一种可用于检测血清中抗BoNT-A中和抗体的间接ELISA。展开更多
基金Project (No.491030-w10011) supported by the Zhejiang Provincial Natural Science Foundation of China
文摘Background and objective:Botulinum toxin type A(BoNT/A)is a metalloprotease that blocks synaptic transmission via the cleavage of a synaptosomal-associated protein of 25 kDa(SNAP-25).It has gained widespread use as a treatment for cerebral palsy and skeletal muscle hypertrophy.In China,Chinese botulinum toxin type A(CBTX-A),a type of BoNT/A,is in widespread clinical use.However,the changes in the morphological and biochemical properties of treated muscles and in remote muscles from the CBTX-A injection site are relatively unknown.Therefore,we investigated the changes in histomorphology and myosin heavy chain(MyHC)isoform composition and distribution in rat gastrocnemius muscles after intramuscular injection of CBTX-A.Methods:The weakness of the injected muscles was assessed periodically to identify their functional deficiency.Muscle slices were stained with hematoxylin-eosin(HE)and adenosine triphosphatase(ATPase).MyHC isoform composition was analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis(SDS-PAGE)to uncover changes in morphological and biochemical properties.Results:Our findings demonstrate that following injection of CBTX-A 5 U into rat gastrocnemius muscles,shifts in MyHC isoform composition emerged on the third day after injection and peaked in the fourth week.The composition remained distinctly different from that of the control group after the twelfth week.More specifically,there was a decrease in the proportion of the type IIb isoform and an increase in the proportions of type IIx,type IIa,and type I isoforms.Conclusions:Data revealed that CBTX-A led to a shift in MyHC composition towards slower isoforms and that the MyHC composition remained far from normal six months after a single injection.However,no noticeable remote muscle weakness was induced.
文摘Background:Benign essential blepharospasm(BEB),aberrant facial nerve degeneration and hemifacial spasm(HFS)are all examples dystonia which,though not life-threatening,can have a significant impact on patient quality of life.The need for reliable self-rating surveys to monitor functional disability is fundamental.The Blepharospasm Disability Index(BSDI)is already a widely utilised and validated selfrating score for blepharospasm whilst the functional disability score(FDS)requires further validation.The principle aim of this study is to repeat validation of the FDS against the BSDI,which has been validated by several groups since its original description but only in patients with BEB.Methods:A randomised blinded prospective cohort study was conducted at a single unit on 38 patients with BEB,aberrant facial nerve degeneration and HFS.Patients were blinded to complete the FDS followed by the BSDI or the BSDI followed by the FDS with a 30-minute interval.Results:Both the FDS and BSDI were found to be reliable with high internal consistency and test-retest reliability.Both scales were also found to be moderately correlated with the Jankovic disease severity score.Conclusions:This study is the first to use the FDS as a rating scale in patients with HFS and aberrant facial nerve degeneration.It is also the first study to formally validate the FDS as an acceptable rating scale for patients with dystonia and in particular it provides validation for its use in patients with HFS and aberrant facial nerve degeneration.
文摘目的建立间接ELISA,检测血清中抗A型肉毒神经毒素(botulinum neurotoxin type A, BoNT-A)中和抗体。方法以纯化的BoNT-A作为包被抗原,抗BoNT-A兔血清作为一抗,辣根过氧化物酶(horseradish peroxidase, HRP)标记的金黄色葡萄球菌蛋白A(Staphylococal Protein A, SPA)作为二抗,结合实验设计,建立检测血清中抗BoNT-A中和抗体的间接ELISA,验证该方法的特异性、灵敏度和重复性,并与经典动物中和试验法检测抗BoNT-A中和抗体的结果进行比较。结果①间接ELISA条件的建立与优化,使用2.50μg/mL纯化的BoNT-A抗原包被,4℃过夜;1%明胶作为封闭剂,37℃封闭2 h;确定一抗优化条件:反应条件为1∶5 000稀释,37℃孵育90 min;二抗优化条件:反应条件为1∶10 000稀释,37℃孵育90 min;加入底物37℃显色10 min,加终止液终止后,用酶标仪测定A450 nm值;②经过验证该方法特异性好,所包被抗原与抗伤寒杆菌兔血清、抗破伤风毒素兔血清、抗B型肉毒毒素兔血清、抗E型肉毒毒素兔血清、抗F型肉毒毒素兔血清均无交叉反应;灵敏度高,当抗BoNT-A兔血清按照1∶320 000稀释时,检测结果依然呈阳性;重复性良好,批内重复性验证CV分别为2.62%、1.40%、2.14%,变异系数均小于3%,批间差异无统计学意义(P=0.103,P>0.05);该方法检测抗BoNT-A中和抗体检出限为抗-0.03 LD50/mL,大约是经典动物中和试验法的1/30,显著地提高了检测灵敏度。结论建立了一种可用于检测血清中抗BoNT-A中和抗体的间接ELISA。
